Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | HRH2 | P25021 | 2/20 | 0.70 |
| ▸ | HTR2A | P28223 | 2/20 | 0.70 |
| ▸ | DRD3 | P35462 | 2/20 | 0.70 |
| ▸ | HTR2B | P41595 | 2/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 2/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | TEK | Q02763 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10931329 | 0.97 | ALDH1A1 (0.69) | HRH1TDP1HRH2HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL10929139 | 0.96 | HRH1 (0.68) | HRH1TDP1HRH2HTR2ADRD3 | |
| SCHEMBL1376101 | 0.93 | HRH1 (0.83) | HRH1TDP1HRH2HTR2ADRD3 | |
| SCHEMBL3847601 | 0.93 | HRH1 (0.83) | HRH1TDP1HRH2HTR2ADRD3 | |
| SCHEMBL3847012 | 0.93 | HRH1 (0.83) | HRH1TDP1HRH2HTR2ADRD3 | |
| SCHEMBL10932202 | 0.93 | HRH1 (0.65) | HRH1TDP1HRH2HTR2ADRD3 | |
| SCHEMBL2058384 | 0.91 | HRH1 (0.80) | HRH1TDP1HRH2HTR2ADRD3 | |
| SCHEMBL11122370 | 0.91 | HRH1 (0.63) | HRH1TDP1HRH2HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL10931633 | 0.90 | HRH1 (0.64) | HRH1TDP1HRH2HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL10930111 | 0.90 | HRH1 (0.80) | HRH1TDP1HRH2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6469009-B1 | MIXTURE CONSISTING ESSENTIALLY OF PSEUDOEPHEDRINE AND COMPOUND SELECTED FROM 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACID OR AMIDE DERIVATIVES, THEIR INDIVIDUAL OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS | UCB, S.A. (BE) | 2002-10-22 | — | — | US | claimed |
| US-20010020023-A1 | Pharmaceutical compositions for the treatment of rhinitis | UCB PHARMA, S.A. (BE) | 2001-09-06 | — | — | US | claimed |
| US-20080206331-A1 | TABLET COMPRISING EFLETIRIZINE AND PSEUDOEPHEDRINE | UCB, S.A. (BE) | 2008-08-28 | — | — | US | disclosed |
| US-20080177071-A1 | Process for the preparation of 2- (2- (4- (bis (4-flourophenyl) methyl) -pipe razin-1-yl) ethoxy acetic acid derivatives or corresponding salt forms thereof and intermediates therefor | DIOUF OUSMANE | 2008-07-24 | — | — | US | disclosed |
| US-20040254375-A1 | Process for the preparation of 2-(2-(4-(bis(4-fluorophenyl)methyl)-piperazin-1-yl)ethoxy)acetic acid derivatives or corresponding salt forms thereof and intermediates therefor | UCB SA (BE) | 2004-12-16 | — | — | US | disclosed |
| EP-1157016-B1 | A PROCESS FOR THE PREPARATION OF 2- 2- 4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY ACETIC ACID COMPOUNDS OR SALTS THEREOF | GEA FARMACEUTISK FABRIK AS (DK) | 2003-10-08 | — | — | EP | disclosed |
| US-6489329-B2 | MIXTURE OF PSEUDOEPHEDRINE AND 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)ACETIC ACID | UCB S.A. (BE) | 2002-12-03 | — | — | US | disclosed |
| US-6469009-B1 | MIXTURE CONSISTING ESSENTIALLY OF PSEUDOEPHEDRINE AND COMPOUND SELECTED FROM 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACID OR AMIDE DERIVATIVES, THEIR INDIVIDUAL OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS | UCB, S.A. (BE) | 2002-10-22 | — | — | US | disclosed |
| EP-1157016-A1 | A PROCESS FOR THE PREPARATION OF 2- 2- 4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY ACETIC ACID COMPOUNDS OR SALTS THEREOF | A/S GEA Farmaceutisk Fabrik (DK) | 2001-11-28 | — | — | EP | disclosed |
| US-20010020023-A1 | Pharmaceutical compositions for the treatment of rhinitis | UCB PHARMA, S.A. (BE) | 2001-09-06 | — | — | US | disclosed |
| EP-1071461-A1 | METHODS AND COMPOSITIONS USING CETIRIZINE IN COMBINATION WITH LEUKOTRIENE INHIBITORS FOR TREATING CONDITIONS RESPONSIVE TO LEUKOTRIENE INHIBITION | SEPRACOR, INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| WO-2000052000-A1 | A PROCESS FOR THE PREPARATION OF 2-{2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY}ACETIC ACID COMPOUNDS OR SALTS THEREOF | A/S GEA FARMACEUTISK FABRIK (DK) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999052553-A1 | METHODS AND COMPOSITIONS USING CETIRIZINE IN COMBINATION WITH LEUKOTRIENE INHIBITORS FOR TREATING CONDITIONS RESPONSIVE TO LEUKOTRIENE INHIBITION | SEPRACOR INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| US-4525358-A | ANTIHISTAMINES, ANTIALLERGENS, ANTISPASMODICS, BRONCHODILATORS | UCB PHARMACEUTICALS, INC. (US) | 1985-06-25 | — | — | US | disclosed |
| EP-0058146-B1 | 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACIDS AND THEIR AMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | U C B, S.A. (BE) | 1984-06-27 | — | — | EP | disclosed |
| EP-0058146-A1 | 2-(4-(Diphenylmethyl)-1-piperazinyl)-acetic acids and their amides, process for their preparation and pharmaceutical compositions | U C B, S.A. (BE) | 1982-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206331-A1 | TABLET COMPRISING EFLETIRIZINE AND PSEUDOEPHEDRINE | HRH4, HRH1, HRH2 | HRH1 2/4885TDP1 2771/4885HRH2 3/4885 |
| US-20080177071-A1 | Process for the preparation of 2- (2- (4- (bis (4-flourophenyl) methyl) -pipe razin-1-yl) ethoxy acetic acid derivatives or corresponding salt forms thereof and intermediates therefor | FAR1, FFAR2, FFAR1 | HRH1 314/4885TDP1 3745/4885HRH2 437/4885 |
| US-20010020023-A1 | Pharmaceutical compositions for the treatment of rhinitis | HRH4, HRH2, HRH1 | HRH1 3/4885TDP1 4206/4885HRH2 2/4885 |
| US-20040254375-A1 | Process for the preparation of 2-(2-(4-(bis(4-fluorophenyl)methyl)-piperazin-1-yl)ethoxy)acetic acid derivatives or corresponding salt forms thereof and intermediates therefor | CYP4F11, CYP4Z1, NR5A1 | HRH1 51/4885TDP1 1739/4885HRH2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.